Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
A multi-center, open-label, long-term study to evaluate the safety and efficacy of AXS-05 in patients with major depressive disorder, including treatment resistant depression, treated for up to one year.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of major depressive disorder, including treatment resistant depression
Body mass index (BMI) between 18 and 40 kg/m\^2, inclusive
Agree to use adequate method of contraception for the duration of the study
Additional criteria may apply
You may not be if
Suicide risk
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Additional criteria may apply
Clareo Health | Open-Label Safety Study of AXS-05 in Subjects With Depression
